Bone marrow transplantation for multiple myeloma

Where we are today

Research output: Contribution to journalArticle

Abstract

Multiple myeloma is incurable with standard chemotherapy. Autologous transplantation appears to offer a modest survival advantage over standard dose chemotherapy, but most patients subsequently relapse. Through the induction of graft-versus-tumor activity, allogeneic bone marrow transplantation can lead to long-term disease-free survival, and cure in some patients with myeloma. Transplant-related mortality after allogeneic bone marrow transplantation is high. Many patients are ineligible for this approach because of advanced age, comorbid illnesses, and extensive previous chemotherapy. Ongoing investigations endeavor to reduce regimen-related mortality through nonmyeloablative preparative regimens while maintaining immunologic antitumor activity through donor lymphocytes, which have significant graft-versus-myeloma activity. Early reports demonstrate lower rates of transplant related mortality; however, graft-versus-host disease rates are high and can preclude the administration of graded donor lymphocyte infusions, which may optimize the therapeutic index of graft-versus-host reactivity.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalCurrent Opinion in Oncology
Volume14
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Multiple Myeloma
Bone Marrow Transplantation
Transplants
Homologous Transplantation
Drug Therapy
Mortality
Tissue Donors
Lymphocytes
Autologous Transplantation
Graft vs Host Disease
Disease-Free Survival
Recurrence
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research

Cite this

Bone marrow transplantation for multiple myeloma : Where we are today. / Huff, Carol Ann; Jones, Richard J.

In: Current Opinion in Oncology, Vol. 14, No. 2, 2002, p. 147-151.

Research output: Contribution to journalArticle

@article{f98bf45401874f7c931e8b5a9f5c997b,
title = "Bone marrow transplantation for multiple myeloma: Where we are today",
abstract = "Multiple myeloma is incurable with standard chemotherapy. Autologous transplantation appears to offer a modest survival advantage over standard dose chemotherapy, but most patients subsequently relapse. Through the induction of graft-versus-tumor activity, allogeneic bone marrow transplantation can lead to long-term disease-free survival, and cure in some patients with myeloma. Transplant-related mortality after allogeneic bone marrow transplantation is high. Many patients are ineligible for this approach because of advanced age, comorbid illnesses, and extensive previous chemotherapy. Ongoing investigations endeavor to reduce regimen-related mortality through nonmyeloablative preparative regimens while maintaining immunologic antitumor activity through donor lymphocytes, which have significant graft-versus-myeloma activity. Early reports demonstrate lower rates of transplant related mortality; however, graft-versus-host disease rates are high and can preclude the administration of graded donor lymphocyte infusions, which may optimize the therapeutic index of graft-versus-host reactivity.",
author = "Huff, {Carol Ann} and Jones, {Richard J}",
year = "2002",
doi = "10.1097/00001622-200203000-00002",
language = "English (US)",
volume = "14",
pages = "147--151",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Bone marrow transplantation for multiple myeloma

T2 - Where we are today

AU - Huff, Carol Ann

AU - Jones, Richard J

PY - 2002

Y1 - 2002

N2 - Multiple myeloma is incurable with standard chemotherapy. Autologous transplantation appears to offer a modest survival advantage over standard dose chemotherapy, but most patients subsequently relapse. Through the induction of graft-versus-tumor activity, allogeneic bone marrow transplantation can lead to long-term disease-free survival, and cure in some patients with myeloma. Transplant-related mortality after allogeneic bone marrow transplantation is high. Many patients are ineligible for this approach because of advanced age, comorbid illnesses, and extensive previous chemotherapy. Ongoing investigations endeavor to reduce regimen-related mortality through nonmyeloablative preparative regimens while maintaining immunologic antitumor activity through donor lymphocytes, which have significant graft-versus-myeloma activity. Early reports demonstrate lower rates of transplant related mortality; however, graft-versus-host disease rates are high and can preclude the administration of graded donor lymphocyte infusions, which may optimize the therapeutic index of graft-versus-host reactivity.

AB - Multiple myeloma is incurable with standard chemotherapy. Autologous transplantation appears to offer a modest survival advantage over standard dose chemotherapy, but most patients subsequently relapse. Through the induction of graft-versus-tumor activity, allogeneic bone marrow transplantation can lead to long-term disease-free survival, and cure in some patients with myeloma. Transplant-related mortality after allogeneic bone marrow transplantation is high. Many patients are ineligible for this approach because of advanced age, comorbid illnesses, and extensive previous chemotherapy. Ongoing investigations endeavor to reduce regimen-related mortality through nonmyeloablative preparative regimens while maintaining immunologic antitumor activity through donor lymphocytes, which have significant graft-versus-myeloma activity. Early reports demonstrate lower rates of transplant related mortality; however, graft-versus-host disease rates are high and can preclude the administration of graded donor lymphocyte infusions, which may optimize the therapeutic index of graft-versus-host reactivity.

UR - http://www.scopus.com/inward/record.url?scp=0036128142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036128142&partnerID=8YFLogxK

U2 - 10.1097/00001622-200203000-00002

DO - 10.1097/00001622-200203000-00002

M3 - Article

VL - 14

SP - 147

EP - 151

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 2

ER -